GlassScriptPhysician profile
Ginette Ndingue
NPI 1770015794
$3,512.15
in general payments reported to CMS, 2019-2025
25 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,090 · 2022: $1,543 · 2023: $759 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $878.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $548.28 | 2021-2023 | Hetlioz, Fanapt |
| Novo Nordisk INC | $497.70 | 2021-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $257.59 | 2021-2023 | Xarelto |
| Gilead Sciences, INC. | $239.96 | 2021-2023 | |
| Abbvie INC. | $206.90 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $204.92 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $176.52 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $134.69 | 2022-2023 | Nuedexta, Rexulti |
| Pfizer INC. | $121.64 | 2021-2023 | |
| Acadia Pharmaceuticals INC | $119.57 | 2021 | |
| Avanir Pharmaceuticals, INC. | $118.77 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $114.86 | 2022 | |
| Sumitomo Pharma America, INC. | $112.85 | 2023 | Aptiom, Gemtesa |
| Abbott Laboratories | $103.79 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $99.81 | 2021-2023 | Lokelma |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $93.95 | 2021-2022 | |
| Lundbeck LLC | $76.57 | 2023 | Rexulti |
| Lilly USA, LLC | $74.27 | 2021-2023 | Amyvid |
| Teva Pharmaceuticals USA, INC. | $39.58 | 2023 | Austedo Xr |
| Amgen INC. | $36.83 | 2023 | Prolia, Evenity |
| Astellas Pharma US INC | $36.63 | 2022 | |
| Ucb, INC. | $36.34 | 2022-2023 | Briviact |
| Daiichi Sankyo INC. | $21.45 | 2022 | |
| Nevro Corp. | $19.60 | 2022 | |
| Sun Pharmaceutical Industries INC. | $19.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginette Ndingue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.